Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate

&times

Overview

What is Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate?

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release is a once daily extended-release, single-entity amphetamine product. Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release combines the neutral sulfate salts of dextroamphetamine and amphetamine, with the dextro isomer of amphetamine saccharate and d,l-amphetamine aspartate monohydrate. The dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsule contains two types of drug-containing beads designed to give a double-pulsed delivery of amphetamines, which prolongs the release of amphetamine from dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release compared to the conventional dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate (immediate-release) tablet formulation.

Inactive Ingredients and Colors



What does Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate look like?



What are the available doses of Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate?

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release 5 mg capsules: Light blue/Orange (printed with and 3062 on the cap and body in black ink).

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release 10 mg capsules: Light blue/Ivory (printed with and 3059 on the cap and body in black ink).

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release 15 mg capsules: Ivory/Orange (printed with and 3063 on the cap and body in black ink).

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release 20 mg capsules: Light blue/Light blue (printed with and 3060 on the cap and body in black ink).

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release 25 mg capsules: Ivory/Ivory (printed with and 3064 on the cap and body in black ink).

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release 30 mg capsules: Orange/Orange (printed with and 3061 on the cap and body in black ink).

What should I talk to my health care provider before I take Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate?

How should I use Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate?

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release, a CNS stimulant, is indicated for the treatment of attention deficit hyperactivity disorder (ADHD). ()

Individualize the dosage according to the therapeutic needs and response of the patient. Administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release at the lowest effective dosage.

Based on bioequivalence data, patients taking divided doses of immediate-release dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate, (for example, twice daily), may be switched to dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release at the same total daily dose taken once daily. Titrate at weekly intervals to appropriate efficacy and tolerability as indicated.

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules may be taken whole, or the capsule may be opened and the entire contents sprinkled on applesauce. If the patient is using the sprinkle administration method, the sprinkled applesauce should be consumed immediately; it should not be stored. Patients should take the applesauce with sprinkled beads in its entirety without chewing. The dose of a single capsule should not be divided. The contents of the entire capsule should be taken, and patients should not take anything less than one capsule per day.

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release may be taken with or without food.

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release should be given upon awakening. Afternoon doses should be avoided because of the potential for insomnia.

Where possible, dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release therapy should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy


What interacts with Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate?

Sorry No Records found


What are the warnings of Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate?

Sorry No Records found


What are the precautions of Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate?

Sorry No Records found


What are the side effects of Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate?

Sorry No records found


What should I look out for while using Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate?

Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release administration is contraindicated in patients with the following conditions:

Amphetamines have a high potential for abuse. Administration of amphetamines for prolonged periods of time may lead to drug dependence. Pay particular attention to the possibility of subjects obtaining amphetamines for non-therapeutic use or distribution to others and the drugs should be prescribed or dispensed sparingly .


What might happen if I take too much Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate?

Manifestations of acute amphetamine overdose with amphetamines include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. Fatigue and depression usually follow the central nervous system stimulation. Serotonin syndrome has been reported with amphetamine use, including dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release. Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma. 

Treatment

The prolonged release of mixed amphetamine salts from dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release should be considered when treating patients with overdose.


How should I store and handle Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate?

Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F)Dispense in tight, light-resistant container.Manufactured by: Yung Shin Pharmaceutical Ind. Co., Ltd. Tachia, Taichung 43769 TAIWAN Distributed by: Carlsbad Technology, Inc. 5923 Balfour Ct., Carlsbad, CA 92008, USA Marketed/ Packaged by: Camarillo, CA 93012 USA To report ADVERSE DRUG EXPERIENCE, please call Carlsbad Technology, Inc. at 1-760-431-8284Revised: 06/14Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F)Dispense in tight, light-resistant container.Manufactured by: Yung Shin Pharmaceutical Ind. Co., Ltd. Tachia, Taichung 43769 TAIWAN Distributed by: Carlsbad Technology, Inc. 5923 Balfour Ct., Carlsbad, CA 92008, USA Marketed/ Packaged by: Camarillo, CA 93012 USA To report ADVERSE DRUG EXPERIENCE, please call Carlsbad Technology, Inc. at 1-760-431-8284Revised: 06/14Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F)Dispense in tight, light-resistant container.Manufactured by: Yung Shin Pharmaceutical Ind. Co., Ltd. Tachia, Taichung 43769 TAIWAN Distributed by: Carlsbad Technology, Inc. 5923 Balfour Ct., Carlsbad, CA 92008, USA Marketed/ Packaged by: Camarillo, CA 93012 USA To report ADVERSE DRUG EXPERIENCE, please call Carlsbad Technology, Inc. at 1-760-431-8284Revised: 06/14Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F)Dispense in tight, light-resistant container.Manufactured by: Yung Shin Pharmaceutical Ind. Co., Ltd. Tachia, Taichung 43769 TAIWAN Distributed by: Carlsbad Technology, Inc. 5923 Balfour Ct., Carlsbad, CA 92008, USA Marketed/ Packaged by: Camarillo, CA 93012 USA To report ADVERSE DRUG EXPERIENCE, please call Carlsbad Technology, Inc. at 1-760-431-8284Revised: 06/14Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F)Dispense in tight, light-resistant container.Manufactured by: Yung Shin Pharmaceutical Ind. Co., Ltd. Tachia, Taichung 43769 TAIWAN Distributed by: Carlsbad Technology, Inc. 5923 Balfour Ct., Carlsbad, CA 92008, USA Marketed/ Packaged by: Camarillo, CA 93012 USA To report ADVERSE DRUG EXPERIENCE, please call Carlsbad Technology, Inc. at 1-760-431-8284Revised: 06/14Store at 25°C (77°F); excursions permitted to 15°C-30°C (59°F-86°F)Dispense in tight, light-resistant container.Manufactured by: Yung Shin Pharmaceutical Ind. Co., Ltd. Tachia, Taichung 43769 TAIWAN Distributed by: Carlsbad Technology, Inc. 5923 Balfour Ct., Carlsbad, CA 92008, USA Marketed/ Packaged by: Camarillo, CA 93012 USA To report ADVERSE DRUG EXPERIENCE, please call Carlsbad Technology, Inc. at 1-760-431-8284Revised: 06/14Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are available as follows:5 mg – Each #3 capsule with light blue opaque cap and orange opaque body printed with and 3062 on the cap and body in black ink contains 1.25 mg of dextroamphetamine saccharate, 1.25 mg of amphetamine aspartate monohydrate, 1.25 mg of dextroamphetamine sulfate USP, and 1.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3062-11) with a child-resistant closure.10 mg – Each #3 capsule with light blue opaque cap and ivory opaque body printed with and 3059 on the cap and body in black ink contains 2.5 mg of dextroamphetamine saccharate, 2.5 mg of amphetamine aspartate monohydrate, 2.5 mg of dextroamphetamine sulfate USP, and 2.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3059-11) with a child-resistant closure.15 mg – Each #2 capsule with ivory opaque cap and orange opaque body printed with and 3063 on the cap and body in black ink contains 3.75 mg of dextroamphetamine saccharate, 3.75 mg of amphetamine aspartate monohydrate, 3.75 mg of dextroamphetamine sulfate USP, and 3.75 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3063-11) with a child-resistant closure.20 mg – Each #2 capsule with light blue opaque cap and light blue opaque body printed with and 3060 on the cap and body in black ink contains 5.0 mg of dextroamphetamine saccharate, 5.0 mg of amphetamine aspartate monohydrate, 5.0 mg of dextroamphetamine sulfate USP, and 5.0 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3060-11) with a child-resistant closure.25 mg – Each #1 capsule with ivory opaque cap and ivory opaque body printed with and 3064 on the cap and body in black ink contains 6.25 mg of dextroamphetamine saccharate, 6.25 mg of amphetamine aspartate monohydrate, 6.25 mg of dextroamphetamine sulfate USP, and 6.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3064-11) with a child-resistant closure.30 mg – Each #1 capsule with orange opaque cap and orange opaque body printed with and 3061 on the cap and body in black ink contains 7.5 mg of dextroamphetamine saccharate, 7.5 mg of amphetamine aspartate monohydrate, 7.5 mg of dextroamphetamine sulfate USP, and 7.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3061-11) with a child-resistant closure.Dispense in a tight, light-resistant container as defined in the USP.Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are available as follows:5 mg – Each #3 capsule with light blue opaque cap and orange opaque body printed with and 3062 on the cap and body in black ink contains 1.25 mg of dextroamphetamine saccharate, 1.25 mg of amphetamine aspartate monohydrate, 1.25 mg of dextroamphetamine sulfate USP, and 1.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3062-11) with a child-resistant closure.10 mg – Each #3 capsule with light blue opaque cap and ivory opaque body printed with and 3059 on the cap and body in black ink contains 2.5 mg of dextroamphetamine saccharate, 2.5 mg of amphetamine aspartate monohydrate, 2.5 mg of dextroamphetamine sulfate USP, and 2.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3059-11) with a child-resistant closure.15 mg – Each #2 capsule with ivory opaque cap and orange opaque body printed with and 3063 on the cap and body in black ink contains 3.75 mg of dextroamphetamine saccharate, 3.75 mg of amphetamine aspartate monohydrate, 3.75 mg of dextroamphetamine sulfate USP, and 3.75 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3063-11) with a child-resistant closure.20 mg – Each #2 capsule with light blue opaque cap and light blue opaque body printed with and 3060 on the cap and body in black ink contains 5.0 mg of dextroamphetamine saccharate, 5.0 mg of amphetamine aspartate monohydrate, 5.0 mg of dextroamphetamine sulfate USP, and 5.0 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3060-11) with a child-resistant closure.25 mg – Each #1 capsule with ivory opaque cap and ivory opaque body printed with and 3064 on the cap and body in black ink contains 6.25 mg of dextroamphetamine saccharate, 6.25 mg of amphetamine aspartate monohydrate, 6.25 mg of dextroamphetamine sulfate USP, and 6.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3064-11) with a child-resistant closure.30 mg – Each #1 capsule with orange opaque cap and orange opaque body printed with and 3061 on the cap and body in black ink contains 7.5 mg of dextroamphetamine saccharate, 7.5 mg of amphetamine aspartate monohydrate, 7.5 mg of dextroamphetamine sulfate USP, and 7.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3061-11) with a child-resistant closure.Dispense in a tight, light-resistant container as defined in the USP.Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are available as follows:5 mg – Each #3 capsule with light blue opaque cap and orange opaque body printed with and 3062 on the cap and body in black ink contains 1.25 mg of dextroamphetamine saccharate, 1.25 mg of amphetamine aspartate monohydrate, 1.25 mg of dextroamphetamine sulfate USP, and 1.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3062-11) with a child-resistant closure.10 mg – Each #3 capsule with light blue opaque cap and ivory opaque body printed with and 3059 on the cap and body in black ink contains 2.5 mg of dextroamphetamine saccharate, 2.5 mg of amphetamine aspartate monohydrate, 2.5 mg of dextroamphetamine sulfate USP, and 2.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3059-11) with a child-resistant closure.15 mg – Each #2 capsule with ivory opaque cap and orange opaque body printed with and 3063 on the cap and body in black ink contains 3.75 mg of dextroamphetamine saccharate, 3.75 mg of amphetamine aspartate monohydrate, 3.75 mg of dextroamphetamine sulfate USP, and 3.75 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3063-11) with a child-resistant closure.20 mg – Each #2 capsule with light blue opaque cap and light blue opaque body printed with and 3060 on the cap and body in black ink contains 5.0 mg of dextroamphetamine saccharate, 5.0 mg of amphetamine aspartate monohydrate, 5.0 mg of dextroamphetamine sulfate USP, and 5.0 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3060-11) with a child-resistant closure.25 mg – Each #1 capsule with ivory opaque cap and ivory opaque body printed with and 3064 on the cap and body in black ink contains 6.25 mg of dextroamphetamine saccharate, 6.25 mg of amphetamine aspartate monohydrate, 6.25 mg of dextroamphetamine sulfate USP, and 6.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3064-11) with a child-resistant closure.30 mg – Each #1 capsule with orange opaque cap and orange opaque body printed with and 3061 on the cap and body in black ink contains 7.5 mg of dextroamphetamine saccharate, 7.5 mg of amphetamine aspartate monohydrate, 7.5 mg of dextroamphetamine sulfate USP, and 7.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3061-11) with a child-resistant closure.Dispense in a tight, light-resistant container as defined in the USP.Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are available as follows:5 mg – Each #3 capsule with light blue opaque cap and orange opaque body printed with and 3062 on the cap and body in black ink contains 1.25 mg of dextroamphetamine saccharate, 1.25 mg of amphetamine aspartate monohydrate, 1.25 mg of dextroamphetamine sulfate USP, and 1.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3062-11) with a child-resistant closure.10 mg – Each #3 capsule with light blue opaque cap and ivory opaque body printed with and 3059 on the cap and body in black ink contains 2.5 mg of dextroamphetamine saccharate, 2.5 mg of amphetamine aspartate monohydrate, 2.5 mg of dextroamphetamine sulfate USP, and 2.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3059-11) with a child-resistant closure.15 mg – Each #2 capsule with ivory opaque cap and orange opaque body printed with and 3063 on the cap and body in black ink contains 3.75 mg of dextroamphetamine saccharate, 3.75 mg of amphetamine aspartate monohydrate, 3.75 mg of dextroamphetamine sulfate USP, and 3.75 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3063-11) with a child-resistant closure.20 mg – Each #2 capsule with light blue opaque cap and light blue opaque body printed with and 3060 on the cap and body in black ink contains 5.0 mg of dextroamphetamine saccharate, 5.0 mg of amphetamine aspartate monohydrate, 5.0 mg of dextroamphetamine sulfate USP, and 5.0 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3060-11) with a child-resistant closure.25 mg – Each #1 capsule with ivory opaque cap and ivory opaque body printed with and 3064 on the cap and body in black ink contains 6.25 mg of dextroamphetamine saccharate, 6.25 mg of amphetamine aspartate monohydrate, 6.25 mg of dextroamphetamine sulfate USP, and 6.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3064-11) with a child-resistant closure.30 mg – Each #1 capsule with orange opaque cap and orange opaque body printed with and 3061 on the cap and body in black ink contains 7.5 mg of dextroamphetamine saccharate, 7.5 mg of amphetamine aspartate monohydrate, 7.5 mg of dextroamphetamine sulfate USP, and 7.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3061-11) with a child-resistant closure.Dispense in a tight, light-resistant container as defined in the USP.Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are available as follows:5 mg – Each #3 capsule with light blue opaque cap and orange opaque body printed with and 3062 on the cap and body in black ink contains 1.25 mg of dextroamphetamine saccharate, 1.25 mg of amphetamine aspartate monohydrate, 1.25 mg of dextroamphetamine sulfate USP, and 1.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3062-11) with a child-resistant closure.10 mg – Each #3 capsule with light blue opaque cap and ivory opaque body printed with and 3059 on the cap and body in black ink contains 2.5 mg of dextroamphetamine saccharate, 2.5 mg of amphetamine aspartate monohydrate, 2.5 mg of dextroamphetamine sulfate USP, and 2.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3059-11) with a child-resistant closure.15 mg – Each #2 capsule with ivory opaque cap and orange opaque body printed with and 3063 on the cap and body in black ink contains 3.75 mg of dextroamphetamine saccharate, 3.75 mg of amphetamine aspartate monohydrate, 3.75 mg of dextroamphetamine sulfate USP, and 3.75 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3063-11) with a child-resistant closure.20 mg – Each #2 capsule with light blue opaque cap and light blue opaque body printed with and 3060 on the cap and body in black ink contains 5.0 mg of dextroamphetamine saccharate, 5.0 mg of amphetamine aspartate monohydrate, 5.0 mg of dextroamphetamine sulfate USP, and 5.0 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3060-11) with a child-resistant closure.25 mg – Each #1 capsule with ivory opaque cap and ivory opaque body printed with and 3064 on the cap and body in black ink contains 6.25 mg of dextroamphetamine saccharate, 6.25 mg of amphetamine aspartate monohydrate, 6.25 mg of dextroamphetamine sulfate USP, and 6.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3064-11) with a child-resistant closure.30 mg – Each #1 capsule with orange opaque cap and orange opaque body printed with and 3061 on the cap and body in black ink contains 7.5 mg of dextroamphetamine saccharate, 7.5 mg of amphetamine aspartate monohydrate, 7.5 mg of dextroamphetamine sulfate USP, and 7.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3061-11) with a child-resistant closure.Dispense in a tight, light-resistant container as defined in the USP.Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are available as follows:5 mg – Each #3 capsule with light blue opaque cap and orange opaque body printed with and 3062 on the cap and body in black ink contains 1.25 mg of dextroamphetamine saccharate, 1.25 mg of amphetamine aspartate monohydrate, 1.25 mg of dextroamphetamine sulfate USP, and 1.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3062-11) with a child-resistant closure.10 mg – Each #3 capsule with light blue opaque cap and ivory opaque body printed with and 3059 on the cap and body in black ink contains 2.5 mg of dextroamphetamine saccharate, 2.5 mg of amphetamine aspartate monohydrate, 2.5 mg of dextroamphetamine sulfate USP, and 2.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3059-11) with a child-resistant closure.15 mg – Each #2 capsule with ivory opaque cap and orange opaque body printed with and 3063 on the cap and body in black ink contains 3.75 mg of dextroamphetamine saccharate, 3.75 mg of amphetamine aspartate monohydrate, 3.75 mg of dextroamphetamine sulfate USP, and 3.75 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3063-11) with a child-resistant closure.20 mg – Each #2 capsule with light blue opaque cap and light blue opaque body printed with and 3060 on the cap and body in black ink contains 5.0 mg of dextroamphetamine saccharate, 5.0 mg of amphetamine aspartate monohydrate, 5.0 mg of dextroamphetamine sulfate USP, and 5.0 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3060-11) with a child-resistant closure.25 mg – Each #1 capsule with ivory opaque cap and ivory opaque body printed with and 3064 on the cap and body in black ink contains 6.25 mg of dextroamphetamine saccharate, 6.25 mg of amphetamine aspartate monohydrate, 6.25 mg of dextroamphetamine sulfate USP, and 6.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3064-11) with a child-resistant closure.30 mg – Each #1 capsule with orange opaque cap and orange opaque body printed with and 3061 on the cap and body in black ink contains 7.5 mg of dextroamphetamine saccharate, 7.5 mg of amphetamine aspartate monohydrate, 7.5 mg of dextroamphetamine sulfate USP, and 7.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3061-11) with a child-resistant closure.Dispense in a tight, light-resistant container as defined in the USP.Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are available as follows:5 mg – Each #3 capsule with light blue opaque cap and orange opaque body printed with and 3062 on the cap and body in black ink contains 1.25 mg of dextroamphetamine saccharate, 1.25 mg of amphetamine aspartate monohydrate, 1.25 mg of dextroamphetamine sulfate USP, and 1.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3062-11) with a child-resistant closure.10 mg – Each #3 capsule with light blue opaque cap and ivory opaque body printed with and 3059 on the cap and body in black ink contains 2.5 mg of dextroamphetamine saccharate, 2.5 mg of amphetamine aspartate monohydrate, 2.5 mg of dextroamphetamine sulfate USP, and 2.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3059-11) with a child-resistant closure.15 mg – Each #2 capsule with ivory opaque cap and orange opaque body printed with and 3063 on the cap and body in black ink contains 3.75 mg of dextroamphetamine saccharate, 3.75 mg of amphetamine aspartate monohydrate, 3.75 mg of dextroamphetamine sulfate USP, and 3.75 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3063-11) with a child-resistant closure.20 mg – Each #2 capsule with light blue opaque cap and light blue opaque body printed with and 3060 on the cap and body in black ink contains 5.0 mg of dextroamphetamine saccharate, 5.0 mg of amphetamine aspartate monohydrate, 5.0 mg of dextroamphetamine sulfate USP, and 5.0 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3060-11) with a child-resistant closure.25 mg – Each #1 capsule with ivory opaque cap and ivory opaque body printed with and 3064 on the cap and body in black ink contains 6.25 mg of dextroamphetamine saccharate, 6.25 mg of amphetamine aspartate monohydrate, 6.25 mg of dextroamphetamine sulfate USP, and 6.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3064-11) with a child-resistant closure.30 mg – Each #1 capsule with orange opaque cap and orange opaque body printed with and 3061 on the cap and body in black ink contains 7.5 mg of dextroamphetamine saccharate, 7.5 mg of amphetamine aspartate monohydrate, 7.5 mg of dextroamphetamine sulfate USP, and 7.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3061-11) with a child-resistant closure.Dispense in a tight, light-resistant container as defined in the USP.Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are available as follows:5 mg – Each #3 capsule with light blue opaque cap and orange opaque body printed with and 3062 on the cap and body in black ink contains 1.25 mg of dextroamphetamine saccharate, 1.25 mg of amphetamine aspartate monohydrate, 1.25 mg of dextroamphetamine sulfate USP, and 1.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3062-11) with a child-resistant closure.10 mg – Each #3 capsule with light blue opaque cap and ivory opaque body printed with and 3059 on the cap and body in black ink contains 2.5 mg of dextroamphetamine saccharate, 2.5 mg of amphetamine aspartate monohydrate, 2.5 mg of dextroamphetamine sulfate USP, and 2.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3059-11) with a child-resistant closure.15 mg – Each #2 capsule with ivory opaque cap and orange opaque body printed with and 3063 on the cap and body in black ink contains 3.75 mg of dextroamphetamine saccharate, 3.75 mg of amphetamine aspartate monohydrate, 3.75 mg of dextroamphetamine sulfate USP, and 3.75 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3063-11) with a child-resistant closure.20 mg – Each #2 capsule with light blue opaque cap and light blue opaque body printed with and 3060 on the cap and body in black ink contains 5.0 mg of dextroamphetamine saccharate, 5.0 mg of amphetamine aspartate monohydrate, 5.0 mg of dextroamphetamine sulfate USP, and 5.0 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3060-11) with a child-resistant closure.25 mg – Each #1 capsule with ivory opaque cap and ivory opaque body printed with and 3064 on the cap and body in black ink contains 6.25 mg of dextroamphetamine saccharate, 6.25 mg of amphetamine aspartate monohydrate, 6.25 mg of dextroamphetamine sulfate USP, and 6.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3064-11) with a child-resistant closure.30 mg – Each #1 capsule with orange opaque cap and orange opaque body printed with and 3061 on the cap and body in black ink contains 7.5 mg of dextroamphetamine saccharate, 7.5 mg of amphetamine aspartate monohydrate, 7.5 mg of dextroamphetamine sulfate USP, and 7.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3061-11) with a child-resistant closure.Dispense in a tight, light-resistant container as defined in the USP.Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules are available as follows:5 mg – Each #3 capsule with light blue opaque cap and orange opaque body printed with and 3062 on the cap and body in black ink contains 1.25 mg of dextroamphetamine saccharate, 1.25 mg of amphetamine aspartate monohydrate, 1.25 mg of dextroamphetamine sulfate USP, and 1.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3062-11) with a child-resistant closure.10 mg – Each #3 capsule with light blue opaque cap and ivory opaque body printed with and 3059 on the cap and body in black ink contains 2.5 mg of dextroamphetamine saccharate, 2.5 mg of amphetamine aspartate monohydrate, 2.5 mg of dextroamphetamine sulfate USP, and 2.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3059-11) with a child-resistant closure.15 mg – Each #2 capsule with ivory opaque cap and orange opaque body printed with and 3063 on the cap and body in black ink contains 3.75 mg of dextroamphetamine saccharate, 3.75 mg of amphetamine aspartate monohydrate, 3.75 mg of dextroamphetamine sulfate USP, and 3.75 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3063-11) with a child-resistant closure.20 mg – Each #2 capsule with light blue opaque cap and light blue opaque body printed with and 3060 on the cap and body in black ink contains 5.0 mg of dextroamphetamine saccharate, 5.0 mg of amphetamine aspartate monohydrate, 5.0 mg of dextroamphetamine sulfate USP, and 5.0 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3060-11) with a child-resistant closure.25 mg – Each #1 capsule with ivory opaque cap and ivory opaque body printed with and 3064 on the cap and body in black ink contains 6.25 mg of dextroamphetamine saccharate, 6.25 mg of amphetamine aspartate monohydrate, 6.25 mg of dextroamphetamine sulfate USP, and 6.25 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3064-11) with a child-resistant closure.30 mg – Each #1 capsule with orange opaque cap and orange opaque body printed with and 3061 on the cap and body in black ink contains 7.5 mg of dextroamphetamine saccharate, 7.5 mg of amphetamine aspartate monohydrate, 7.5 mg of dextroamphetamine sulfate USP, and 7.5 mg of amphetamine sulfate USP. Capsules are supplied in bottles of 100 (NDC 0228-3061-11) with a child-resistant closure.Dispense in a tight, light-resistant container as defined in the USP.Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The mode of therapeutic action in ADHD is not known. Amphetamines are thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.

Non-Clinical Toxicology
Dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release administration is contraindicated in patients with the following conditions:

Amphetamines have a high potential for abuse. Administration of amphetamines for prolonged periods of time may lead to drug dependence. Pay particular attention to the possibility of subjects obtaining amphetamines for non-therapeutic use or distribution to others and the drugs should be prescribed or dispensed sparingly .

Oxcarbazepine can inhibit CYP2C19 and induce CYP3A4/5 with potentially important effects on plasma concentrations of other drugs. In addition, several AEDs that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and MHD.

Oxcarbazepine was evaluated in human liver microsomes to determine its capacity to inhibit the major cytochrome P450 enzymes responsible for the metabolism of other drugs. Results demonstrate that oxcarbazepine and its pharmacologically active 10-monohydroxy metabolite (MHD) have little or no capacity to function as inhibitors for most of the human cytochrome P450 enzymes evaluated (CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, CYP4A9 and CYP4A11) with the exception of CYP2C19 and CYP3A4/5. Although inhibition of CYP3A4/5 by oxcarbazepine and MHD did occur at high concentrations, it is not likely to be of clinical significance. The inhibition of CYP2C19 by oxcarbazepine and MHD, however, is clinically relevant (see below).

In vitro, the UDP-glucuronyl transferase level was increased, indicating induction of this enzyme. Increases of 22% with MHD and 47% with oxcarbazepine were observed. As MHD, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., valproic acid, lamotrigine).

In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.

As binding of MHD to plasma proteins is low (40%), clinically significant interactions with other drugs through competition for protein binding sites are unlikely.

Sudden Death and Pre-existing Structural Cardiac Abnormalities or Other Serious Heart Problems

Children and Adolescents

Adults

.

Hypertension and Other Cardiovascular Conditions

Assessing Cardiovascular Status in Patients being Treated with Stimulant Medications

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).